Nanostructured Silicon‐Based Materials as a Drug Delivery System for Water‐Insoluble Drugs

Lehto, Vesa‐Pekka; Salonen, Jarno; Santos, Hélder A.; Riikonen, Joakim

doi:10.1002/9781118444726.ch15

Cited by 12 publications

(3 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was demonstrated by loading bevacizumab (avastin) into pSi and the concentration factor was defined as the ratio of the mass of the avastin in the pSi film per unit volume to the mass of drug in the initial loading solution per unit volume. In addition, loading of a drug inside pSi pores prevents crystallization providing a better control over drug availability and dissolution profile [21,108]. pSi particles are able to protect sensitive proteins from degradation and enzymatic denaturation in the stomach [109].…”

Section: Porous Silicon As a Platform For Drug Delivery Applicationsmentioning

confidence: 99%

Porous silicon for drug delivery applications and theranostics: recent advances, critical review and perspectives

Kumeria

McInnes

Maher

et al. 2017

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

Porous silicon (pSi) engineered by electrochemical etching has been used as a drug delivery vehicle to address the intrinsic limitations of traditional therapeutics. Biodegradability, biocompatibility, and optoelectronic properties make pSi a unique candidate for developing biomaterials for theranostics and photodynamic therapies. This review presents an updated overview about the recent therapeutic systems based on pSi, with a critical analysis on the problems and opportunities that this technology faces as well as highlighting pSi's growing potential. Areas covered: Recent progress in pSi-based research includes drug delivery systems, including biocompatibility studies, drug delivery, theranostics, and clinical trials with the most relevant examples of pSi-based systems presented here. A critical analysis about the technical advantages and disadvantages of these systems is provided along with an assessment on the challenges that this technology faces, including clinical trials and investors' support. Expert opinion: pSi is an outstanding material that could improve existing drug delivery and photodynamic therapies in different areas, paving the way for developing advanced theranostic nanomedicines and incorporating payloads of therapeutics with imaging capabilities. However, more extensive in-vivo studies are needed to assess the feasibility and reliability of this technology for clinical practice. The technical and commercial challenges that this technology face are still uncertain.

show abstract

Section: Porous Silicon As a Platform For Drug Delivery Applicationsmentioning

confidence: 99%

Porous silicon for drug delivery applications and theranostics: recent advances, critical review and perspectives

Kumeria

McInnes

Maher

et al. 2017

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

show abstract

“…Today many thousands of synthetic drugs are available and drug delivery is a multibillion euro market with hundreds of companies developing formulations that improve efficacy and safety (Ranade and Cannon 2011). The use of nanotechnology and nanostructured materials is also being increasingly investigated in this field (Kumar et al 2013). …”

Section: Introductionmentioning

confidence: 98%

Drug Delivery with Porous Silicon

Salonen¹

2014

Handbook of Porous Silicon

Self Cite

View full text Add to dashboard Cite

“…1). This is very promising because of the increasing number of new challenges the pharmaceutical industry is currently facing, in order to increase bioavailability of new drug candidates (Ranade and Cannon 2011;Lehto et al 2013).…”

Section: Introductionmentioning

confidence: 99%

Drug Delivery with Porous Silicon

Salonen¹

2016

Handbook of Porous Silicon

Self Cite

View full text Add to dashboard Cite

Biodegradable porous silicon is under preclinical assessment for a range of drug delivery applications, and in this updated review, data is now available on more than 30 active pharmaceutical ingredients (API). Studies to date on oral, subcutaneous, intravenous, intravitreal, and intratumoral modes of delivery are covered. Sustained delivery of an increasing range of biological actives, like peptides and antibodies, is under evaluation, as are bioavailability enhancements for small hydrophobic APIs. Both the merits and existing challenges of this nanostructured carrier are raised.

show abstract

Nanostructured Silicon‐Based Materials as a Drug Delivery System for Water‐Insoluble Drugs

Cited by 12 publications

References 88 publications

Porous silicon for drug delivery applications and theranostics: recent advances, critical review and perspectives

Porous silicon for drug delivery applications and theranostics: recent advances, critical review and perspectives

Drug Delivery with Porous Silicon

Drug Delivery with Porous Silicon

Contact Info

Product

Resources

About